Actinium Pharmaceuticals (NYSE:ATNM) Cut to Sell at StockNews.com

StockNews.com downgraded shares of Actinium Pharmaceuticals (NYSE:ATNM) from a hold rating to a sell rating in a research report report published on Monday morning.

Separately, HC Wainwright restated a “buy” rating and set a $4.00 price target on shares of Actinium Pharmaceuticals in a research report on Monday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $4.00.

Actinium Pharmaceuticals Stock Performance

ATNM opened at $1.46 on Monday. Actinium Pharmaceuticals has a 52-week low of $1.03 and a 52-week high of $10.14. The stock has a market capitalization of $45.55 million, a PE ratio of -1.05 and a beta of -0.24. The stock’s 50 day moving average price is $1.38 and its 200-day moving average price is $1.35.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Several hedge funds have recently made changes to their positions in ATNM. Barclays PLC boosted its position in shares of Actinium Pharmaceuticals by 323.0% during the third quarter. Barclays PLC now owns 42,935 shares of the company’s stock valued at $81,000 after purchasing an additional 32,784 shares in the last quarter. Vontobel Holding Ltd. bought a new stake in Actinium Pharmaceuticals in the fourth quarter worth $32,000. Los Angeles Capital Management LLC boosted its holdings in Actinium Pharmaceuticals by 25.0% in the fourth quarter. Los Angeles Capital Management LLC now owns 213,950 shares of the company’s stock worth $270,000 after acquiring an additional 42,770 shares in the last quarter. Creative Financial Designs Inc. ADV boosted its holdings in Actinium Pharmaceuticals by 42.7% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 91,007 shares of the company’s stock worth $115,000 after acquiring an additional 27,222 shares in the last quarter. Finally, Sei Investments Co. bought a new stake in Actinium Pharmaceuticals in the fourth quarter worth $62,000. 27.50% of the stock is currently owned by institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).